Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company has two market proprietary products, DecisionDx-Melanoma and DecisionDx-UM, and have two active proprietary products in development DecisionDx-UM and DecisionDx-Melanoma. The Company is developing a treatment plan for certain cancers using clinical and pathology factors. Its lead product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP), a test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer.
Day Range Brought:51.16-52.00
SYROS PHARMACEUMATICALS INC
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline
...